title: The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial.
abstract: Much controversy surrounds the use of high-sensitivity C-reactive protein (hs-CRP) as a marker of cardiovascular (CV) risk. Although data regarding the association of hs-CRP with CV disease is extensive and consistent, its role in clinical practice remains unclear. The American Heart Association (AHA) recently published a scientific statement regarding criteria for evaluation of novel markers of CV risk. This article provides a comprehensive review of data regarding hs-CRP as a risk marker for CV disease in the context of these AHA criteria. The impact of the JUPITER trial on the utility of hs-CRP as a risk marker is emphasized. The review concludes with an evidence-based statement regarding the current role of hs-CRP in CV risk prediction.
authors.affiliation: Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA. Tabd@emory.edu
authors.forename: Thura T
authors.initials: TT
authors.lastname: Abd
authors.forename: Danny J
authors.initials: DJ
authors.lastname: Eapen
authors.forename: Ambareesh
authors.initials: A
authors.lastname: Bajpai
authors.forename: Abhinav
authors.initials: A
authors.lastname: Goyal
authors.forename: Allen
authors.initials: A
authors.lastname: Dollar
authors.forename: Laurence
authors.initials: L
authors.lastname: Sperling
mesh_terms: D015415:Biomarkers / Q000032:analysis / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D019317:Evidence-Based Medicine; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D008297:Male; D011237:Predictive Value of Tests; D011743:Pyrimidines / Q000627:therapeutic use*; D011859:Radiography; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D018570:Risk Assessment; D000068718:Rosuvastatin Calcium; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein